1 week Ago By ABMN Staff
Norges Bank purchased a new stake in shares of Summit Therapeutics Inc. ( NASDAQ:SMMT – Free Report ) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 100,000 shares of the company’s stock, valued at approximately $1,784,000.
Several other institutional investors and hedge funds also recently bought and sold shares of SMMT. Steward Partners Investment Advisory LLC boosted its holdings in shares of Summit Therapeutics by 56.1% in the fourth quarter.
Steward Partners Investment Advisory LLC now owns 2,503 shares of the company’s stock worth $45,000 after acquiring an additional 900 shares during the period. CIBC Asset Management Inc boosted its stake in Summit Therapeutics by 5.5% in the 4th quarter.
CIBC Asset Management Inc now owns 21,577 shares of the company’s stock worth $385,000 after purchasing an additional 1,132 shares during the period. Brooklyn Investment Group bought a new position in Summit Therapeutics in the 4th quarter worth about $29,000. Rakuten Securities Inc.
purchased a new position in Summit Therapeutics during the 4th quarter valued at about $71,000. Finally, Janney Montgomery Scott LLC increased its position in shares of Summit Therapeutics by 39.4% during the fourth quarter.
Janney Montgomery Scott LLC now owns 15,716 shares of the company’s stock valued at $280,000 after buying an additional 4,443 shares during the period. 4.61% of the stock is owned by institutional investors.
Analyst Ratings Changes A number of equities analysts have recently commented on SMMT shares. Evercore ISI assumed coverage on shares of Summit Therapeutics in a research report on Wednesday, March 12th. They issued an “outperform” rating and a $30.
00 price objective for the company. HC Wainwright restated a “buy” rating and set a $44.00 price target on shares of Summit Therapeutics in a research report on Tuesday, February 25th.
Truist Financial initiated coverage on shares of Summit Therapeutics in a report on Wednesday, January 8th. They issued a “buy” rating and a $35.00 price target on the stock.
Cantor Fitzgerald initiated coverage on Summit Therapeutics in a research note on Friday, March 21st. They set an “overweight” rating for the company. Finally, StockNews.
com upgraded Summit Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, March 5th. One research analyst has rated the stock with a hold rating and ten have assigned a buy rating to the stock. According to MarketBeat.
com, Summit Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $35.40. Summit Therapeutics Stock Performance NASDAQ:SMMT opened at $23.
24 on Friday. Summit Therapeutics Inc. has a fifty-two week low of $2.
10 and a fifty-two week high of $33.89. The firm has a market cap of $17.
14 billion, a PE ratio of -83.00 and a beta of -0.46.
The business has a 50 day moving average price of $19.70 and a 200-day moving average price of $19.66.
Summit Therapeutics ( NASDAQ:SMMT – Get Free Report ) last announced its quarterly earnings results on Monday, February 24th. The company reported ($0.08) earnings per share for the quarter, meeting the consensus estimate of ($0.
08). The firm had revenue of $0.20 million for the quarter.
Research analysts predict that Summit Therapeutics Inc. will post -0.3 EPS for the current year.
Summit Therapeutics Company Profile ( Free Report ) Summit Therapeutics Inc, a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company’s lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. Further Reading Receive News & Ratings for Summit Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Summit Therapeutics and related companies with MarketBeat.
com's FREE daily email newsletter ..
